Eledon Pharmaceuticals

Tokai Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for prostate cancer and other hormone-driven diseases. Its lead candidate drug is galeterone, an oral small molecule currently undergoing various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s androgen receptor degradation drug discovery program focuses on identifying and developing compounds for patients with androgen receptor signaling diseases, including prostate cancer. On January 4, 2021, Tokai Pharmaceuticals announced its official name change to Eledon Pharmaceuticals, Inc.